Vitalibis Appoints Dr. Steven Zodkoy as Founding Member of Scientific Advisory Board
Newly Formed Scientific Advisory Board to Focus on Research, Education and Awareness For Premium Hemp-Based Wellness Products
Dr. Zodkoy to Address the Association of New Jersey Chiropractors Spring Summit on Saturday, May 18th
LAS VEGAS, May 17, 2019 (GLOBE NEWSWIRE) -- Vitalibis, Inc. (OTCQB: VCBD), a technology based formulator of premium hemp-based wellness products, has appointed industry thought-leader Dr. Steven Zodkoy, DC, CNS, DACBN as the founding member of its Scientific Advisory Board to assist with research, education and awareness initiatives surrounding its premium hemp-based wellness products with naturally occurring cannabidiol.
Dr. Steven Zodkoy is a board-certified chiropractor, nutritionist, kinesiologist and industry thought-leader who, for over twenty years, has specialized in treating patients who have been deemed "untreatable" through a standard course of treatment. Dr. Zodkoy attended Rutgers University and received his bachelor’s degree and Doctor of Chiropractic degree from Los Angeles College of Chiropractic at the age of twenty-four.
Dr. Zodkoy is the author of the Amazon best-seller Misdiagnosed: The Adrenal Fatigue Link, which examines how adrenal fatigue has been linked to many health conditions and the best methods to diagnose and treat these conditions.
Dr. Zodkoy currently operates a practice in Freehold, New Jersey, where he regularly lectures to groups in his community and holds continuing education courses for medical professionals. On May 18th, Dr. Zodkoy will address the Association of New Jersey Chiropractors Spring Summit on a panel titled ‘The Opioid Epidemic: An Integrated Approach to Patient Care’.
“Consumers naturally have an abundance of health and wellness questions related to products containing full spectrum hemp oil,” said Steve Raack, Chief Executive Officer of Vitalibis. “Unfortunately, there is an excess of misinformation regarding these products being promoted online. We believe that adding a trusted, widely respected industry thought-leader like Dr. Zodkoy will go a long way to educating the public as to the benefits of safe, premium, full-spectrum hemp oil.”
“As a strong proponent of finding alternative solutions for medical issues deemed untreatable, I am incredibly honored to act as the founding member of Vitalibis’ Scientific Advisory Board,” said Dr. Steven Zodkoy. “I personally found the company’s unique commitment to sustainability, safety and transparency in this emerging industry particularly refreshing. I look forward to leveraging my industry experience to add value to Vitalibis’ customer education initiatives.”
About Vitalibis, Inc.
Vitalibis (OTCQB: VCBD) is a socially conscious brand focused on people, products and the planet. We are a technology-based formulator of premium, full spectrum phytocannabinoid rich hemp products with naturally occurring cannabidiol, along with safe personal care and nutritional products. Our Ambassador program combines the best elements of social selling, ecommerce and affiliate marketing into one innovative program - empowering our people and social mission driven ecosystem. For additional information, please visit www.vitalibis.com.
FORWARD LOOKING STATEMENTS
This news release includes forward-looking statements that reflect Vitalibis Inc. current expectations about its future results, performance, prospects and opportunities Vitalibis, Inc. has tried to identify these forward-looking statements by using words and phrases such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "should", "typical", "we are confident" or similar expressions. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities for the remainder of 2019 and beyond to differ materially from those expressed in, or implied by, these forward-looking statements.
Released May 17, 2019